Core Viewpoint - The company has adjusted the maximum repurchase price of its shares from RMB 50.00 per share to RMB 49.5367 per share following the implementation of the 2024 annual profit distribution plan [1][2][3] Summary by Sections 1. Basic Information on Share Repurchase - The company plans to repurchase its shares using its own funds through the Shanghai Stock Exchange, with a total repurchase amount between RMB 100 million and RMB 200 million within 12 months from the board's approval date [1] 2. Reasons for Adjusting the Maximum Repurchase Price - The adjustment is due to the company's decision to distribute a cash dividend of RMB 4.7 per 10 shares to all shareholders, which affects the base for calculating the repurchase price [2][3] 3. Details of the Price Adjustment - The new maximum repurchase price is calculated as follows: (previous maximum price - cash dividend per share) / (1 + change in circulating shares ratio). The cash dividend per share is approximately RMB 0.4633 based on the total shares participating in the distribution [3] 4. Estimated Repurchase Quantity - With the adjusted maximum repurchase price of RMB 49.5367, the company estimates it can repurchase approximately 4.0374 million shares, representing about 1.27% of the total share capital, based on the upper limit of RMB 200 million [4] 5. Other Matters - Other aspects of the share repurchase plan remain unchanged, and the company will adhere to relevant regulations while making repurchase decisions based on market conditions [5]

青岛海尔生物医疗股份有限公司 关于 2024 年年度权益分派实施后调整回购股份 价格上限的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 重要内容提示： 青岛海尔生物医疗股份有限公司（以下简称"公司"）2024 年年度权益 分派实施后，公司以集中竞价交易方式回购股份价格上限由不超过人民币 50.00 元/股（含）调整为不超过人民币 49.5367 元/股（含）。 一、回购股份的基本情况 公司于 2025 年 1 月 13 日召开第三届董事会第四次会议，审议通过了《关于 以集中竞价交易方式回购公司股份方案的议案》（以下简称"本次回购方案"）， 同意公司以自有资金通过上海证券交易所股票交易系统以集中竞价交易方式回 购公司已发行的部分人民币普通股（A 股）。回购的股份将在未来适宜时机全部 用于员工持股计划或股权激励，回购价格不超过 50 元/股（含），回购资金总额 不低于人民币 10,000 万元（含），不超过人民币 20,000 万元（含），回购期限自 公司董事会审议通过本次回购方案之日起 12 个月内。具体内容详见公 ...

证券代码：688139 证券简称：海尔生物 公告编号：2025-038 青岛海尔生物医疗股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/1/14 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 1 1 月 13 | 年 | 月 | 14 | 日~2026 | 年 | 日 | | 预计回购金额 | 10,000万元~20,000万元 | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 1,375,725股 | | | | | | | | 累计已回购股数占总股本比例 | 0.4327% | | ...

Core Viewpoint - The company announced a cash dividend distribution of CNY 0.47 per share for the fiscal year 2024, approved at the annual shareholders' meeting on April 29, 2025 [2][3]. Distribution Plan - The dividend distribution is based on the total share capital after deducting shares held in the company's repurchase account, resulting in a total of 313,425,953 shares eligible for the dividend [4][6]. - The total cash dividend to be distributed amounts to CNY 147,310,197.91 (including tax) [4]. - The cash dividend per share is calculated as approximately CNY 0.4633 after adjustments for the total share capital [6]. Implementation Details - The cash dividends will be distributed through China Securities Depository and Clearing Corporation Limited, Shanghai Branch, to shareholders registered by the end of the trading day on the record date [8]. - Shareholders who have not completed designated trading will have their dividends held by the clearing company until the trading is completed [8]. Taxation Information - Individual shareholders holding shares for over one year are exempt from personal income tax on dividends, while those holding for one year or less will have taxes calculated upon the sale of shares [10][11]. - For qualified foreign institutional investors (QFII), a withholding tax of 10% will apply, resulting in a net dividend of CNY 0.423 per share [12].

差异化权益分派特殊除权除息事项的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"、"保荐机构"）作为青 岛海尔生物医疗股份有限公司（以下简称"海尔生物"、"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上 海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管 指引第 1 号——规范运作》等法律、行政法规、部门规章及业务规则，对海尔 生物本次差异化权益分派特殊除权除息事项发表意见如下： 一、本次差异化分红的原因 国泰海通证券股份有限公司 关于青岛海尔生物医疗股份有限公司 公司于 2022 年 2 月 6 日召开第二届董事会第五次会议，审议通过了《关于 以集中竞价交易方式回购公司股份方案的议案》，同意公司以自有资金通过上海 证券交易所交易系统以集中竞价交易方式回购公司已发行的部分人民币普通股 股票。回购的股份将在未来适宜时机全部用于员工持股计划或股权激励，回购 价格不超过 100 元/股（含），回购资金总额不低于人民币 5,000 万元（含），不 超过人民币 10,000 万元（含），回购期限自公司董事会审议通过回购方案之日 起 12 个月内。 ...

证券代码：688139 证券简称：海尔生物 公告编号：2025-037 青岛海尔生物医疗股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承 担法律责任。 重要内容提示： 每股现金红利0.47元 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/5 | 2025/6/6 | 2025/6/6 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经青岛海尔生物医疗股份有限公司（以下简称"公司"）2025 年 4 月 29 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东， 是否涉及差异化分红送转：是 每股分配比例 但根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号 ——回购股份》等有关规定，公司回购 ...

Core Viewpoint - Haier Biomedical's stock closed at 30.92 yuan, down 1.34%, with a rolling PE ratio of 28.98 times, and a total market value of 9.831 billion yuan [1] Company Overview - Qingdao Haier Biomedical Co., Ltd. focuses on providing optimal user experiences for life science users, including pharmaceutical companies, research institutions, and healthcare users, forming two main business segments: life sciences and medical innovation [2] - The company offers comprehensive digital solutions represented by smart laboratories, digital hospitals, and smart public health, with key products including low-temperature storage boxes, automated biological sample storage, and various automated medication products [2] Financial Performance - In Q1 2025, the company reported revenue of 689 million yuan, a year-on-year increase of 0.30%, and a net profit of 110 million yuan, a year-on-year decrease of 19.88%, with a gross profit margin of 48.35% [3] - The company's PE ratio is significantly lower than the industry average of 48.92 times and the industry median of 35.68 times, ranking 66th in the industry [3]

Group 1 - The trend of Chinese medical device companies "going global" is long-term positive, especially in the upstream supply chain which has formed a certain scale [1] - In Q1 2025, China's medical device export trade total is projected to reach 69.26 billion yuan, a year-on-year increase of 5.03%, with high-end medical devices seeing significant growth [1] - The export value of China's medical device industry is expected to reach 48.75 billion USD in 2024, reflecting a year-on-year growth of 7.3% [1] Group 2 - Over 100 listed medical device companies have already initiated "going global" operations in 2024, covering various product areas such as medical consumables and diagnostic equipment [2] - Companies are advised to consider business, supply chain, and localization strategies for global expansion [2][3] - Localized production and supply chain management are essential for adapting to market demands in different regions [3] Group 3 - Companies like Haier Bio emphasize the importance of localizing product design and marketing to enhance user experience in overseas markets [4] - The trend of "going global" is common among mature, growth, and startup medical device companies, focusing on high-value and high-end products [6] - High-value medical devices, such as deep brain stimulators, require careful economic calculations and long-term service planning before entering foreign markets [6] Group 4 - Companies are encouraged to leverage digitalization and smart technologies to enhance their global strategies, as seen with Mindray Medical's remote monitoring capabilities [7] - Brand building is crucial for domestic medical device companies, with strategies including sponsorship of international sports events to enhance global influence [7] - The medical device market in Europe and the US accounts for over 65% of the global market share, making it a primary target for Chinese companies [8] Group 5 - Key conditions for Chinese medical device companies to "go global" include having sufficient capital, production capacity, and independent R&D capabilities [8] - Collaboration with local hospitals and doctors for joint R&D and clinical trials can facilitate product entry into new markets [8]

Core Viewpoint - Haier Biomedical's stock closed at 31.9 yuan, down 1.09%, with a rolling PE ratio of 29.90 times, and a total market value of 10.143 billion yuan [1] Group 1: Company Overview - Haier Biomedical focuses on providing optimal user experiences for life science users, including pharmaceutical companies, research institutions, and healthcare users [2] - The company has developed two main business segments: life sciences and medical innovation, offering comprehensive digital solutions such as smart laboratories and digital hospitals [2] - Key products include low-temperature storage boxes, automated biological sample storage systems, and various automated medication products [2] Group 2: Financial Performance - In the first quarter of 2025, the company reported revenue of 689 million yuan, a year-on-year increase of 0.30%, and a net profit of 110 million yuan, a year-on-year decrease of 19.88% [3] - The gross profit margin for sales was 48.35% [3] Group 3: Market Position - The average PE ratio for the medical device industry is 48.98 times, with a median of 36.16 times, placing Haier Biomedical at the 70th position in the industry [1][3] - As of the first quarter of 2025, 14 institutions held shares in Haier Biomedical, with a total holding of 200.17 million shares valued at 6.922 billion yuan [1]

Company Overview - Qingdao Haier Biomedical Co., Ltd. focuses on providing optimal user experiences for life science users, including pharmaceutical and biological enterprises, research institutions, hospitals, and public health organizations [2] - The company has developed two main business segments: life sciences and medical innovation, offering comprehensive digital solutions such as smart laboratories and digital hospitals [2] Financial Performance - For Q1 2025, the company reported revenue of 689 million yuan, a year-on-year increase of 0.30%, and a net profit of 110 million yuan, representing a year-on-year decrease of 19.88% [3] - The gross profit margin for the period was 48.35% [3] Market Position - As of May 6, the company's stock closed at 31.95 yuan, with a rolling price-to-earnings (PE) ratio of 29.94 times, and a total market capitalization of 10.159 billion yuan [1] - The average PE ratio in the medical device industry is 48.90 times, with a median of 36.41 times, placing the company at the 69th position in the industry ranking [1] Shareholder Information - As of March 31, 2025, the number of shareholders for the company was 12,793, a decrease of 453 from the previous count, with an average holding value of 352,800 yuan per shareholder and an average holding of 27,600 shares [1] Product and Innovation - The company's main products include low-temperature storage boxes, automated biological sample storage systems, and various automated medication products, among others [2] - In 2022, the company received several prestigious awards and certifications, enhancing its reputation in the life sciences and medical innovation sectors [2]